Skip to main content

Table 4 MAX41 VOI method relative median differences (%) of MATV, SUV metrics and TLG to corresponding values of EARL1 reconstruction along with 25th and 75th percentiles. Values marked with * indicate that the difference is statistically significant (p < 0.05)

From: Quantitative implications of the updated EARL 2019 PET–CT performance standards

Cancer typeReconstructionMATVSUVmaxSUVpeakSUVmeanTLGTumor SUVmax/liver SUVmaxTumor SUVmax/liver SUVmean
Lung cancerEARL_V2-22* (-31/-15)30* (22/35)23* (14/25)25* (18/36)-1 (-5/2)18* (12/22)29* (23/35)
EARL_V2F60 (-6/2)3* (1/6)5* (4/7)3* (2/6)2 (-1/4)N/AN/A
EARL_V2F79 (1/14)-3 (-8/0)1 (-2/3)-2 (-7/0)4 (-2/8)6* (1/9)-3 (-8/0)
LymphomaEARL_V2-28* (-36/-19)35* (22/41)24* (17/29)37* (23/42)-3* (-8/1)26* (14/30)35* (22/41)
EARL_V2F6-7* (-12/-2)6* (2/13)6* (3/11)6* (0/12)0 (-4/4)N/AN/A
EARL_V2F70 (-5/7)0 (-4/4)2 (-2/4)0 (-4/4)0 (-5/5)6* (1/8)0 (-4/4)
Both combinedEARL_V2-27* (-33/-18)33* (22/40)23* (16/28)34* (22/40)-2* (-7/2)22* (14/29)34* (23/39)
EARL_V2F6-5* (-11/1)5* (1/11)5* (3/9)5* (2/9)1 (-3/4)N/AN/A
EARL_V2F72 (-4/11)-1 (-6/4)2* (-2/4)-1 (-5/4)2 (-4/7)6* (1/9)-1 (-6/3)